<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122340</url>
  </required_header>
  <id_info>
    <org_study_id>Polyprenols</org_study_id>
    <nct_id>NCT03122340</nct_id>
  </id_info>
  <brief_title>Polyprenols (Ropren) in Acute Coronary Syndrome</brief_title>
  <acronym>POLYNCOR</acronym>
  <official_title>Single-center Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Polyprenols (ROPREN) in Subjects With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine efficacy and safety of polyprenols (ROPREN) using in
      patients with acute coronary syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is randomized double blind placebo controlled. Patients with acute coronary
      syndrome taking standard therapy including atorvastatin 40 mg/day were randomized into 2
      groups: group 1 takes Ropren 8 drops 3 times per day for 3 week, then 5 drops 3 times per day
      for 5 weeks; group 2 take placebo in the same dose regimen. The hepatoprotective,
      hypolipidemic, antiinflammatory, cognitive, antidepression functions evaluates after one and
      two - month therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center double-blind, randomized, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ð¡ardiospecific enzymes</measure>
    <time_frame>At 9 days after acute coronary syndrome</time_frame>
    <description>The levels of CK, CK-MB, Troponin I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic enzymes</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>The levels of AST, ALT, Alkaline phosphatase, Gamma glutamine transferase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory enzymes</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>CRP, Interleukin-6, products of lipid peroxidation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>Cognitive function test evolution: Montreal Cognitive Assessment Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>Cholesterol, triglycerides, lipoproteins high density, lipoproteins low density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>Total and direct</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function Anxiety</measure>
    <time_frame>At 2 months after acute coronary syndrome</time_frame>
    <description>Cognitive function test evolution: Sheehan Anxiety Rating Scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyprenol Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropren</intervention_name>
    <description>Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks</description>
    <arm_group_label>Polyprenol Group</arm_group_label>
    <other_name>Polyprenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oil</intervention_name>
    <description>Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome

          -  Informed consent received

        Exclusion Criteria:

          -  Patient`s incapacity to take accurately drops by oneself

          -  Cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey V Popov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tomsk NRMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Research Institute</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tomsk National Research Medical Center of the Russian Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Evgeny V. Vyshlov</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Polyprenols</keyword>
  <keyword>Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

